T he guidelines for the management of severe sepsis and septic shock recommend norepinephrine or dopamine as firstline vasopressor agents (1) . As a result of desensitization of adrenergic receptors in sepsis, however, the shock often becomes catecholamine-resistant (2, 3) . Therefore, alternative (nonadrenergic) treatment strategies for cardiovascular support are urgently needed.
Arginine vasopressin (AVP) has been repeatedly demonstrated to provide beneficial effects on renal function and catecholamine requirements in patients with septic shock (4 -6) . However, AVP may reduce cardiac index and global oxygen transport (7) , thereby potentially threat-ening tissue perfusion (8) . From a physiological point of view, combining a vasopressin analog with a positive inotropic agent appears to be a rational approach. Although dobutamine is currently recommended as the inotrope of choice (1) , its efficacy may also be blunted in advanced sepsis and "the potential benefits of dobutamine need to be weighed against the risk of cardiovascular complications resulting from high-doses" (9) .
Notably, the calcium sensitizer levosimendan increases myocardial contractility at low energy costs independent from the adrenergic system (10) . Although AVP and levosimendan are increasingly used as "rescue drugs" in critically ill patients, the combination of both nonadrenergic compounds as a first-line therapy has not yet been investigated.
We hypothesized that a first-line therapy of septic shock with combined low- dose AVP and levosimendan, supplemented with open-label norepinephrine, is more effective in restoring cardiovascular and pulmonary functions than a first-line therapy with AVP supplemented with norepinephrine or norepinephrine alone. Therefore, the present study was designed as a prospective, randomized, controlled laboratory experiment to elucidate the effects of these treatment strategies in an established ovine model of fulminant septic shock resulting from generalized fecal peritonitis (11, 12) .
MATERIALS AND METHODS

Instrumentation and Surgical Procedures.
After approval by the Local Animal Research Committee, female sheep were anesthetized, mechanically ventilated, and instrumented for chronic hemodynamic monitoring using an established protocol (11, 12) . Details on the instrumentation and surgical procedures are provided in an online supplement (see Supplemental Digital Content 1, http://links.lww.com/CCM/A164).
Experimental Protocol. After baseline (BL) measurements, autologous feces were injected into the peritoneal cavity through an intraperitoneal suction catheter. When septic shock had developed (shock time [ST]; defined as mean arterial pressure Ͻ60 mm Hg), a second set of measurements was performed. The animals were then randomly assigned to receive a first-line therapy of AVP (American Regent Inc, Shirley, NY) (0.5 mU⅐kg Ϫ1 ⅐min Ϫ1 ; equivalent to 0.035 U⅐min Ϫ1 in a 70-kg patient [Vasopressin and Septic Shock Trial: 0.01-0.03 U⅐min Ϫ1 ]; n ϭ 7), combined AVP (0.5 mU⅐kg Ϫ1 ⅐min Ϫ1 [according to clinical recommendations (13, 14) ]) and levosimendan (0.2 g⅐kg Ϫ1 ⅐min Ϫ1 ; n ϭ 7; Simdax; Abbott, IL), or normal saline (n ϭ 7; B. Braun Melsungen AG, Melsungen, Germany). Open-label norepinephrine (Arterenol; Aventis Pharma, Frankfurt, Germany) was additionally titrated to maintain mean arterial pressure at 70 Ϯ 5 mm Hg in all groups, if necessary. To ensure normovolemia, continuous infusions of balanced isotonic crystalloids (Sterofundin ISO; B. Braun) and 6% hydroxyethyl starch 130/0.4 (Voluven; Fresenius Kabi, Bad Homburg, Germany) were increased to 8 mL⅐kg Ϫ1 ⅐h Ϫ1 and 4 mL⅐kg Ϫ1 ⅐h Ϫ1 , respectively, after ST. Additional fluids (crystalloid/colloid ratio 2:1) were infused if hematocrit increased vs. BL (11) .
Hemodynamic Measurements, Blood Gas, Laboratory, and Histologic Analyses. Details on hemodynamic measurements, arterial and mixed venous blood gas as well as laboratory, histologic, and immunohistochemical analyses are provided in the online supplement (see Sup-plementalDigitalContent1,http://links.lww.com/ CCM/A164). Animals surviving the 24-hr study period after ST were killed under deep anesthesia with a lethal dose of 7.45% potassium chloride. After death, tissue samples of lung, heart, liver, kidney, and ileum were stored for histologic and immunohistochemical analyses as previously described (11) .
Statistical Analyses. Analysis of variance methodologies appropriate for two-factor experiments with repeated measures across time for each animal were used. Sigma Stat 3.1 software (Systat Software, Inc, San Jose, CA) was used to perform the statistical analyses. Each variable was analyzed separately for differences among groups and times and for the group-by-time interaction. No statistical analyses were performed at 16 hrs after ST, because only two animals in the AVP ϩ norepinephrine and one in the sole norepinephrine group were still alive at this time point. Specific post hoc, pairwise comparisons among groups were performed using error b along with the Newman-Keuls procedure to adjust for the elevated false-positive rate found otherwise in multiple testings. Survival time was calculated using a log-rank test. Data are summarized and presented as mean Ϯ SEM. Differences were generally considered as statistically significant when p was Ͻ.05.
RESULTS
Baseline Characteristics. There were no differences among study groups in any of the investigated variables at BL or ST. Mean body weight (39 Ϯ 1 kg) and time to onset of septic shock (7 Ϯ 1 hrs) did not differ between groups.
Cardiopulmonary Hemodynamics. Changes in cardiopulmonary variables are presented in Figure 1 and Table 1 . Septic shock was characterized by decreases in mean arterial pressure, systemic vascular resistance index (ST: p Ͻ .001 vs. BL each), and left ventricular stroke work index (ST: p Ͻ .05 vs. BL each) but no significant changes in heart rate or cardiac index. After initiation of aggressive volume resuscitation and group-specific treatments, there was an increase in mean arterial pressure (4 hrs: p Ͻ .001 vs. ST each), heart rate, and cardiac index in all study groups (8 hrs: p Ͻ .05 vs. ST each). When compared with AVP ϩ norepinephrine and sole norepinephrine animals, treatment with combined AVP, levosimendan, and norepinephrine increased left ventricular stroke work indices at similar or lower ventricular filling pressures (pulmonary artery occlusion pressures [ Fig. 2] ). In addition, right ventricular stroke work index was higher in the AVP ϩ levosimendan ϩ norepinephrine group as compared with norepinephrine treatment alone at 12 hrs (Table 1) .
Systemic vascular resistance index decreased in the AVP ϩ levosimendan ϩ norepinephrine group as compared with ST. However, there were no significant differences among study groups. In both nonadrenergic treatment groups, cumu- lative doses of open-label norepinephrine were lower during the first 8 hrs after ST than in norepinephrine animals (all p Ͻ .05; Fig. 3 ).
Mean pulmonary arterial pressure increased in all study groups after ST (12 hrs: p Ͻ .05 vs. ST each). However, ani-mals treated with AVP ϩ levosimendan ϩ norepinephrine had a significantly lower mean pulmonary arterial pressure than sheep allocated to the AVP ϩ norepinephrine (4 hrs) and the sole norepinephrine group (8 hrs) ( Table 1) . Whereas pulmonary vascular resistance did not change in the AVP ϩ norepinephrine and norepinephrine group, it decreased in the AVP ϩ levosimendan ϩ norepinephrine group (Fig. 1A) .
Surrogate Parameters of Perfusion. Variables of global oxygen transport revealed a significant increase in mixed venous oxygen saturation in the AVP ϩ levosimendan ϩ norepinephrine group as compared with the AVP ϩ norepinephrine group at 8 hrs and 12 hrs after ST ( Table 2) . Arterial pH as well as base excess decreased and arterial lactate levels increased within the observation period (p Ͻ .05 vs. ST each; Table 2 ) without statistical significant differences among study groups. In addition, there were no statistical significant differences in mesenteric blood flow among groups (Table 1) .
Pulmonary Gas Exchange. Infusion of AVP ϩ levosimendan ϩ norepinephrine was associated with a higher PaO 2 /FIO 2 ratio compared with the AVP ϩ norepinephrine group at 12 hrs (p ϭ .031) and norepinephrine animals from 8 to 12 hrs (p Ͻ .05 each; Fig. 1B) .
Capillary Leakage. In all study groups, there was a marked decrease in plasma protein concentrations (BL: 4.0 Ϯ 0.2 g⅐dL Ϫ1 vs. 2.5 Ϯ 0.6 g⅐dL Ϫ1 ; p Ͻ .001) that progressed over time (12 hrs: 1.2 Ϯ 0.1 g⅐dL Ϫ1 ; p Ͻ .001 vs. ST). Notably, colloid osmotic pressures were higher in animals treated with AVP ϩ levosimendan ϩ norepinephrine than in both other groups (p Ͻ .05 each; Table 3 ). In addition, hematocrit was lower in the AVP ϩ levosimendan ϩ norepinephrine group than in the AVP ϩ norepinephrine (8 hrs: p ϭ .013) and the sole norepinephrine group (8 hrs: p ϭ .004; Table 2 ). How-ever, total fluid administration (p ϭ .041 vs. norepinephrine; p ϭ .001 vs. AVP ϩ norepinephrine; Fig. 4A ) as well as cumulative net fluid balance (p ϭ .029 vs. norepinephrine; p ϭ .037 vs. AVP ϩ norepinephrine; Fig. 4B ) were lower in the AVP ϩ levosimendan ϩ norepinephrine group than in the AVP ϩ norepinephrine or the sole norepinephrine group.
Laboratory Variables of Inflammation and Organ Function. Systemic inflammation was evidenced by increases in core body temperature (BL: 39.1 Ϯ 0.2°C; 12 hrs: 40.4 Ϯ 0.2°C; p Ͻ .001) and serum amyloid A concentrations (BL: 93 Ϯ 28 mg⅐L Ϫ1 ; 12 hrs: 334 Ϯ 18 mg⅐L Ϫ1 ; p Ͻ .001) in all study groups. Except for a lower lactate dehydrogenase activity in the AVP ϩ levosimendan ϩ norepinephrine group after 4 hrs (p ϭ .003 vs. norepinephrine, p ϭ .04 vs. AVP ϩ norepinephrine), no differences occurred in surrogate parameters of organ dysfunction of the heart and liver among groups (Table 3 ). Both AVP groups had lower plasma urea levels 12 hrs after ST as compared with the norepinephrine group. Similarly, there was a strong tendency toward reduced plasma creatinine levels in the AVP ϩ levosimendan ϩ norepinephrine group as compared with norepinephrine animals (p ϭ .062). The urinary protein/creatinine ratio was markedly lower in animals treated with AVP ϩ levosimendan ϩ norepinephrine (691 Ϯ 194) than in the AVP ϩ norepinephrine (3389 Ϯ 1087) and the norepinephrine groups (3633 Ϯ 1809) after 12 hrs (each p Ͻ .05).
Survival Time. With the exception of two animals treated with AVP ϩ levosimendan ϩ norepinephrine, all animals died within the observation period ( groups (p ϭ .013 vs. AVP ϩ norepinephrine; p ϭ .003 vs. norepinephrine). Histologic Analyses. Histologic analyses of the liver, heart, ileum, and lung revealed moderate to severe inflammatory infiltrates and edema formation with no differences among groups (Fig. 6A-C) . The mean alveolar obstruction score was 7 Ϯ 1 for the control and 8 Ϯ 2 for both nonadrenergic treatment groups (nonsignificant). Kidney samples showed detachment of epithelial cells, severe damage of tubular cells, and intratubular protein precipitation in all animals (Fig. 6D) .
Immunohistochemical Analyses. Immunohistochemical analyses of lung tissue revealed no significant differences in hemeoxygenase-1 activity among study groups (Fig. 7A ). 3-nitrotyrosine concentrations in animals treated with AVP ϩ levosimendan ϩ norepinephrine were lower than in the norepinephrine group (p ϭ .028; Fig. 7B ).
DISCUSSION
The major findings of the present study are that the nonadrenergic, first-line com-bination therapy of AVP and levosimendan supplemented with norepinephrine 1) did not increase cumulative norepinephrine requirements; 2) increased left ventricular stroke work indices at similar or lower ventricular filling pressures; 3) decreased net fluid balance; 4) improved pulmonary function; 5) limited nitrosative stress; and 6) slightly prolonged survival as compared with first-line AVP supplemented with norepinephrine and standard hemodynamic support with norepinephrine alone.
All animals developed a hypotensive, hyperdynamic circulation as typically seen in human septic shock (15) . In addition, multiple organ failure was evidenced by vascular, myocardial, pulmonary, and renal dysfunction. Despite aggressive fluid resuscitation, there was hemoconcentration rather than hemodilution in all study groups. In conjunction with the reduction in plasma protein levels and the positive fluid balance, these findings indicate the presence of capillary leakage (16) . Notably, AVP ϩ levosimendan ϩ norepinephrine therapy was associated with a reduction in hematocrit, fluid requirements, and positive net fluid balance as well as higher colloid osmotic pressures as compared with both other groups despite similar pulmonary artery occlusion pressures. These observations suggest a reduction in capillary leakage. In this context, Traber et al (17) observed that vasopressin analogs may decrease edema formation through V 1a receptor agonism in ovine septic shock. Beneficial effects of levosimendan on endothelial barrier function were reported in advanced chronic heart failure (18) . Levosimendan limited the activation of soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1. It is most likely that the combination of AVP with levosimendan probably had synergistic effects in this regard. The continuous decrease in systemic vascular resistance index despite incremental norepinephrine doses in the norepinephrine group indicated a catecholaminerefractory shock. Both nonadrenergic treatment strategies effectively stabilized hemodynamics and reduced cumulative norepinephrine requirements. Whereas such effect is known for AVP (6, 11, 19) , it appears somewhat surprising for the combination with levosimendan, because levosimendan exerts vasodilatory properties by stimulating adenosine triphosphate-dependent potassium channels. Therefore, an in- crease in norepinephrine requirements as compared with the AVP ϩ norepinephrine group would be expected. In harmony with these pharmacologic considerations, Cunha-Goncalves et al have reported that levosimendan alone (0.83 g⅐kg Ϫ1 ⅐min Ϫ1 ) not only aggravated arterial hypotension and tachycardia, but also increased mortality in endotoxemic pigs (20, 21) . Notably, these pigs seemed to have been hypovolemic, as suggested by the hypodynamic response to endotoxin. Clinical recommendations, however, suggest that levosimendan should only be given in euvolemic patients and in doses not exceeding 0.2 g⅐kg Ϫ1 ⅐min Ϫ1 (13, 14) . Considering these published recommendations, the improvement in myocardial performance in response to levosimendan probably compensated its vasodilatory effects in the present study. Furthermore, the combination with a vasopressor agent appears to be rational to avoid a significant drop in mean arterial pressure (13) .
Although different effects of AVP on myocardial performance and cardiac index are reported in the literature (22, 23) , recent studies suggest that AVP may reduce myocardial contractility (5, 24, 25) . In agreement with these findings, first-line AVP supplemented with norepinephrine in the present study was associated with a lower cardiac index and no increase in left ventricular stroke work index as compared with sole norepinephrine animals at 4 hrs after ST. Notably, the combination with levosimendan not only prevented myocardial depression without any obvious side effects, but also improved left ventricular function as evidenced by higher left ventricular stroke work indices at similar cardiac filling pressures.
The beneficial effects of levosimendan on myocardial function are based on three predominant mechanisms: first, levosimendan exerts positive inotropic effects by increasing the sensitivity of contractile myofilaments to calcium independent of ␤-adrenergic signaling (10, 13) . Second, levosimendan decreases ventricular afterload through activation of adenosine triphosphate-dependent potassium channels in endothelial smooth muscle cells (26 -28) . Finally, levosimendan may provide cardioprotective properties as a result of activation of mitochondrial adenosine triphosphate-dependent potassium channels (29, 30) . In two randomized, controlled studies that investigated the role of levosimendan (0.2 g⅐kg Ϫ1 ⅐min Ϫ1 ) in the treatment of septic shock, Morelli et al (31, 32) also ob-served improved left and right ventricular function as well as reduced pulmonary vascular resistance.
In the present study, low-dose AVP supplemented with norepinephrine did not cause any deterioration in surrogate parameters of tissue perfusion (mesenteric blood flow, global oxygen transport, arterial lactate concentrations) as compared with sole norepinephrine. A potential explanation for this finding represents the sufficient fluid resuscitation. In this context, Asfar et al (33, 34) even reported improved splanchnic blood flow in response to the synthetic vasopressin analog terlipressin and effective volume therapy, whereas terlipressin infusion without appropriate fluid substitution was harmful. Levosimendan has been shown to improve intestinal blood flow and global oxygen transport as compared with placebo and dobutamine in an experimental study in endotoxemic sheep (35) . The lack of improvement in mesenteric blood flow in the AVP ϩ levosimendan ϩ norepinephrine group might be explained by the combination of levosimendan with vasopressor agents, whereas levosimendan was administered as a single therapy in the latter study. Notably, the combination of AVP ϩ levosimendan ϩ norepinephrine improved venous oxygen saturation as compared with AVP ϩ norepinephrine. If this increase in venous oxygen saturation was caused by improved tissue perfusion or the improved gas exchange in the AVP ϩ levosimendan ϩ norepinephrine group (significantly higher PaO 2 /FIO 2 ratios Ͼ300 mm Hg) remains speculative.
Contrary, norepinephrine and AVP ϩ norepinephrine-treated animals suffered from acute respiratory distress syndrome (PaO 2 /FIO 2 ratio Ͻ200 mm Hg; Fig. 1B ). Besides the reduction in capillary leakage, the attenuation of nitrosative stress in the lung probably contributed to the improved pulmonary function in the AVP ϩ levosimendan ϩ norepinephrine group. This assumption is supported by previous experimental studies on acute lung injury (36, 37) .
Compared with norepinephrine and AVP ϩ norepinephrine-treated animals, AVP ϩ levosimendan ϩ norepinephrine attenuated renal dysfunction as suggested by lower urinary protein/creatinine ratios, an index of kidney injury (38) . In addition, plasma levels of creatinine tended to be lower in the AVP ϩ levosimendan ϩ norepinephrine group as compared with the sole norepinephrine animals. Future studies are warranted to determine if the beneficial renal effects were caused by an increased perfusion resulting from activated endothelial adenosine triphosphate-dependent potassium channels (39) or by cytoprotective effects secondary to activation of mitochondrial adenosine triphosphate-dependent potassium channels (40) .
As a result of the high mortality rate in the present study, the clinical relevance of absolute survival times is limited and these data should, therefore, not be overestimated. However, the prolonged survival in the AVP ϩ norepinephrine as compared with the norepinephrine group encourages the hypothesis derived from a predefined subgroup analysis of the recent Vasopressin and Septic Shock Trial, suggesting treatment initiation of AVP early in the course of sepsis. Accordingly, the fact that the nonadrenergic, first-line therapy of combined AVP and levosimendan supplemented with norepinephrine slightly, but significantly, prolonged survival as compared with AVP ϩ norepinephrine (approximately 130%) or standard treatment with sole norepinephrine (approximately 160%) requires further confirmation.
Furthermore, direct translation into clinical practice is limited by the immediate treatment initiation, the lack of source control, and the fact that the current study was performed in previously healthy animals. The majority of patients, however, typically have comorbidities and are treated with delay. In addition, combining vasoactive agents that act on numerous receptors complicates to refer a certain effect to one mechanism caused by one compound. Finally, the risk of false-positive results in a study with numerous outcome variables and time points has to be taken into consideration.
CONCLUSIONS
In summary, the present study provides evidence that the nonadrenergic, first-line treatment consisting of combined AVP and levosimendan supplemented with openlabel norepinephrine improves myocardial, vascular, pulmonary, and renal function and slightly prolongs survival as compared with first-line AVP supplemented with norepinephrine or standard treatment with norepinephrine alone in ovine septic shock. Future studies are now needed to compare the nonadrenergic combination of AVP and levosimendan with the stan-dard therapy consisting of norepinephrine and dobutamine.
